Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.1.151

Lung Cancer in Women: A Single Institution Experience with 50 Patients  

Babacan, Nalan Akgul (Department of Medical Oncology, University of Cumhuriyet)
Yucel, Birsen (Department of Radiation Oncology, University of Cumhuriyet)
Kilickap, Saadettin (Department of Medical Oncology, SIVAS, University of Hacettepe)
Seker, Mehmet Metin (Department of Medical Oncology, University of Cumhuriyet)
Kacan, Turgut (Department of Medical Oncology, University of Cumhuriyet)
Olcas, Ilknur Koc (Department of Internal Medicine, University of Cumhuriyet)
Eren, Ayfer Ay (Department of Radiation Oncology, University of Cumhuriyet)
Odabas, Hatice (Medical Oncology Department, Kartal Education and Research Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.1, 2014 , pp. 151-154 More about this Journal
Abstract
Background: Lung cancer is the most common cause of cancer-related death worldwide. The incidence of lung cancer is aproximately 7-8 thousand percent in Turkish women. In this study, we aimed to evaluate the clinical, pathological properties and survival data of female patients with lung cancer who were treated in our center. Materials and Methods: From 2007 to 2012, 50 women with lung cancer were enrolled. Patient data were evaluated retrospectively. Results: The median age was 61 (40-81). Forty patients (80%) were diagnosed with non small cell lung cancer (NSCLC), 10 patients (20%) were small cell carcinoma (SCC). Twelve (24%) patients were smokers and 13 of 16 non-smokers had a history of exposure to asbestos. The most common histologic subtype was adenocarcinoma (46%) and this accounted for 71% in patients with exposure to asbestos. The most common initial Eastern Cooperative Oncology Group (ECOG) performance score was 1 (24 patients, 48%) and initial stage was IV (25 patients, 50%) in the study group. During the median 15 months (1-96 months) followup period: 1 year overall survival (OS) was 68%, 2year overall survival was 36% and the median survival time was 19 months. According to univariate analysis, poor ECOG performance status, advanced stage, anemia and weight loss at time of diagnosis were negative prognostic factors. However, adenocarcinoma sub-type was a positive prognostic factor. Conclusions: In this study NSCLC sub-type, poor ECOG performance score, advanced stage, anemia and weight loss were prognostic factors in Turkish women with lung cancer.
Keywords
Chemotherapy; female gender; prognosis; lung cancer; survival; Turkey;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Seyfikli Z, Gonlugur U, Sumer H, Topcu S (2001). Sivas'ta Ev Kadinlarinda Sigara Aliskanliklari (Smoking habits housewiwes in Sivas). Tuberkuloz ve Toraks Dergisi, 49, 37-40,
2 Stanley KE (1980). Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst, 65, 25-32.
3 Taioli E WE (1994). Endocrin factors and adenocarcinoma of the lung in women. J Natl Cancer Inst, 86, 869-70.   DOI   ScienceOn
4 TurkStat, global adult tabacco survey, 2012.
5 Visbal AL, Williams BA, Nichols FC, et al (2004).Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg, 78, 209-15.   DOI
6 Wakelee HA, Wang W, Schiller JH, et al (2006). Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol, 1, 441-6.   DOI
7 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.   DOI   ScienceOn
8 Mould RF, Williams RJ (1982). Survival of histologically proven carcinoma of the lung registered in the North West Thames Region, 1975-1979. Br J Cancer, 46, 999-1003.   DOI
9 Nakamura H, Ando K, Shinmyo T, et al (2011). Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg, 17, 469-80.   DOI
10 Olak J, Colson Y (2004). Gender differences in lung cancer: have we really come a long way, baby? J Thorac Cardiovasc Surg, 128, 346-51.   DOI
11 Pirker R, Pereira JR, Szczesna A, et al (2012). Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer, 77, 376-82.   DOI
12 Pitz MW, Musto G, Navaratnam S (2013). Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. Can Respir J, 20, 30-4.
13 Radzikowska E, Glaz P, Roszkowski K (2002). Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol, 13, 1087-93.   DOI   ScienceOn
14 Ramalingam S, Pawlish K, Gadgeel S, et al (1998). Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol, 16, 651-7,
15 Raul Barrera-Rodriguez JM-F: (2012). Lung cancer in women. Targets Therapy, 3, 79-89,
16 Reck M, Thatcher N, Smit EF, et al (2012). Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer, 78, 276-81.   DOI
17 Gupta D BP, Gaborieau V, Jindal SK (2001). Risk factors of lung cancer in Chandigarh, India. Indian J Med Res, 113, 142-50.
18 Demirci E, Daloglu F, Gundogdu C, et al (2013). Incidence and clinicopathologic features of primary lung cancer: a North-Eastern Anatolia region study in Turkey (2006-2012). Asian Pac J Cancer Prev, 14, 1989-93.   과학기술학회마을   DOI   ScienceOn
19 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
20 Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A (2006). Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol, 24, 59-63.   DOI   ScienceOn
21 Inal A, Kaplan MA, Kucukoner M, Karakus A, Isikdogan A (2012). Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatinbased chemotherapy: a retrospective analysis of single institution. J Buon, 17, 533-6.
22 Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907.   DOI   ScienceOn
23 Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.   DOI   ScienceOn
24 La Vecchia C, Bosetti C, Lucchini F, et al (2010). Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol, 21, 1323-60.   DOI   ScienceOn
25 Lissowska J, Bardin-Mikolajczak A, Fletcher T, et al (2005). Lung cancer and indoor pollution from heating and cooking with solid fuels: the IARC international multicentre casecontrol study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol, 162, 326-33.   DOI
26 Bouchardy C, Benhamou S, Schaffar R, et al (2011). Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer, 117, 1288-95.   DOI
27 Albain KS UJ, Gotay CC (2007). For the Southwest Oncology Group Lung Committee: Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol, 25, 7549.
28 Brownson RC, Alavanja MC, Hock ET, Loy TS (1992). Passive smoking and lung cancer in nonsmoking women. Am J Public Health, 82, 1525-30.   DOI   ScienceOn
29 Berardi R, Brunelli A, Tamburrano T, et al (2005). Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer, 49, 371-6.   DOI
30 Boehm DU, Lebrecht A, Schmidt M, et al (2007). Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res, 27, 1223-6.
31 Caro JJ, Salas M, Ward A, Goos G (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer, 91, 2214-21.   DOI
32 Cerfolio RJ, Bryant AS, Scott E, et al (2006). Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest, 130, 1796-802.   DOI
33 Darby S, Hill D, Doll R (2001). Radon: a likely carcinogen at all exposures. Ann Oncol, 12, 1341-51.   DOI
34 Darby S, Hill D, Deo H, et al (2006). Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scand J Work Environ Health, 32, 1-83.   DOI
35 Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Teresa AZ (2011). Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res, 170, 75-83.   DOI   ScienceOn
36 Schrump DS, Giaccone G, Kelsey CR, Marks LB (2008). Nonsmall cell lung cancer. In 'Cancer: Principles & Practice of Oncology', 8th Edition, eds DeVita VT, Lawrence TS, Rosenberg, SA. Lippincott Williams & Wilkins, Philadelphia. pp:896-946.
37 Wheatley-Price P, Blackhall F, Lee SM, et al (2010). The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol, 21, 2023-8,   DOI
38 Wu AH HB, Pike MC, Yu MC (1985). Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst, 74, 747-51.
39 Sasco AJ, Secretan MB, Straif K (2004). Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer, 45, 3-9.
40 Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.   DOI   ScienceOn
41 Sculier JP, Chansky K, Crowley JJ, Van Meerbeek J, Goldstraw P (2008). The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol, 3, 457-66.   DOI   ScienceOn